CACNG7

Summary

CACNG7 (calcium voltage-gated channel auxiliary subunit gamma 7, HGNC:13626) is a protein-coding gene on chromosome 19q13.42, encoding Voltage-dependent calcium channel gamma-7 subunit (P62955). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit.

The protein encoded by this gene is a type II transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type I TARP and a calcium channel gamma subunit.

Source: NCBI Gene 59284 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 41 total — 1 likely-pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_031896

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13626
Approved symbol	CACNG7
Name	calcium voltage-gated channel auxiliary subunit gamma 7
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000105605
Ensembl biotype	protein_coding
OMIM	606899
Entrez	59284

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000222212, ENST00000391766, ENST00000391767, ENST00000468076

RefSeq mRNA: 2 — MANE Select: NM_031896 NM_001384801, NM_031896

CCDS: CCDS12868

Canonical transcript exons

ENST00000391767 — 6 exons

Exon	Start	End
ENSE00000724876	53914500	53914586
ENSE00001122959	53941470	53941615
ENSE00001509686	53942036	53943950
ENSE00001509687	53912803	53913027
ENSE00003606090	53915365	53915505
ENSE00003911033	53909278	53909517

Expression profiles

Bgee: expression breadth ubiquitous, 110 present calls, max score 97.19.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9562 / max 75.7450, expressed in 487 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177435	2.6092	472
177436	0.2943	188
177434	0.0526	21

Top tissues by expression

233 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	97.19	gold quality
right frontal lobe	UBERON:0002810	96.30	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.57	gold quality
anterior cingulate cortex	UBERON:0009835	95.50	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.19	gold quality
cerebellar hemisphere	UBERON:0002245	94.85	gold quality
cerebellar cortex	UBERON:0002129	94.69	gold quality
prefrontal cortex	UBERON:0000451	94.23	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.21	gold quality
amygdala	UBERON:0001876	91.56	gold quality
ganglionic eminence	UBERON:0004023	91.53	gold quality
cerebellum	UBERON:0002037	91.18	gold quality
hypothalamus	UBERON:0001898	90.34	gold quality
putamen	UBERON:0001874	89.31	gold quality
nucleus accumbens	UBERON:0001882	88.50	gold quality
spinal cord	UBERON:0002240	88.46	gold quality
caudate nucleus	UBERON:0001873	88.21	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.88	gold quality
neocortex	UBERON:0001950	87.64	gold quality
ventricular zone	UBERON:0003053	87.57	gold quality
frontal cortex	UBERON:0001870	86.66	gold quality
cerebral cortex	UBERON:0000956	82.68	gold quality
brain	UBERON:0000955	82.33	gold quality
forebrain	UBERON:0001890	82.04	gold quality
substantia nigra	UBERON:0002038	80.70	gold quality
pancreatic ductal cell	CL:0002079	78.58	silver quality
Ammon’s horn	UBERON:0001954	78.58	gold quality
midbrain	UBERON:0001891	76.27	gold quality
temporal lobe	UBERON:0001871	73.19	gold quality
adenohypophysis	UBERON:0002196	73.01	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.46

Regulation

Is transcription factor: no

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cacng7a	ENSDARG00000063006
danio_rerio	cacng7b	ENSDARG00000070624
mus_musculus	Cacng7	ENSMUSG00000069806
rattus_norvegicus	Cacng7	ENSRNOG00000056257
drosophila_melanogaster	stg1	FBGN0288700
caenorhabditis_elegans		WBGENE00007670

Paralogs (5): CACNG3 (ENSG00000006116), CACNG5 (ENSG00000075429), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG2 (ENSG00000166862)

Protein

Protein identifiers

Voltage-dependent calcium channel gamma-7 subunit — P62955 (reviewed: P62955)

Alternative names: Neuronal voltage-gated calcium channel gamma-7 subunit, Transmembrane AMPAR regulatory protein gamma-7

All UniProt accessions (2): P62955, A0A0C4DFY2

UniProt curated annotations — full annotation on UniProt →

Function. Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit. Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization. Displays subunit-specific AMPA receptor regulation. Shows specificity only for GRIA1 and GRIA2.

Subunit / interactions. Interacts with CACNA1C. Identified in a complex with the L-type calcium channel subunits CACNA1C, CACNA2D1 and either CACNB1 or CACNB2. Acts as an auxiliary subunit for AMPA-selective glutamate receptors (AMPARs), such as GRIA1 and GRIA2.

Subcellular location. Cell membrane.

Tissue specificity. Detected in heart left ventricle. Widely expressed.

Similarity. Belongs to the PMP-22/EMP/MP20 family. CACNG subfamily.

RefSeq proteins (2): NP_001371730, NP_114102* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR008368	VDCC_gsu	Family
IPR008371	VDCC_g7su	Family
IPR051072	CACNG_subunit	Family

Pfam: PF13903

UniProt features (9 total): transmembrane region 4, modified residue 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P62955-F1	71.34	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 222, 225, 273

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-5576892	Phase 0 - rapid depolarisation
R-HSA-5576893	Phase 2 - plateau phase
R-HSA-9856532	Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9855142	Cellular responses to mechanical stimuli

MSigDB gene sets: 168 (showing top): GOBP_POSITIVE_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, GOBP_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, KEGG_MAPK_SIGNALING_PATHWAY, GOBP_GROWTH, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEUROGENESIS, HATADA_METHYLATED_IN_LUNG_CANCER_DN, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION

GO Biological Process (11): calcium ion transport (GO:0006816), transmission of nerve impulse (GO:0019226), regulation of mRNA stability (GO:0043488), positive regulation of synaptic transmission, glutamatergic (GO:0051968), postsynaptic neurotransmitter receptor diffusion trapping (GO:0098970), neurotransmitter receptor localization to postsynaptic specialization membrane (GO:0099645), positive regulation of dendrite extension (GO:1903861), regulation of AMPA receptor activity (GO:2000311), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), calcium ion transmembrane transport (GO:0070588)

GO Molecular Function (5): voltage-gated calcium channel activity (GO:0005245), calcium channel regulator activity (GO:0005246), channel regulator activity (GO:0016247), calcium channel activity (GO:0005262), protein binding (GO:0005515)

GO Cellular Component (11): early endosome (GO:0005769), plasma membrane (GO:0005886), voltage-gated calcium channel complex (GO:0005891), AMPA glutamate receptor complex (GO:0032281), neuronal cell body (GO:0043025), cerebellar mossy fiber (GO:0044300), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), L-type voltage-gated calcium channel complex (GO:1990454), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Cardiac conduction	2
Cellular responses to mechanical stimuli	1
Muscle contraction	1
Cellular responses to stimuli	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
postsynaptic membrane	2
receptor localization to synapse	2
regulation of postsynaptic membrane neurotransmitter receptor levels	2
postsynaptic specialization membrane	2
calcium channel activity	2
metal ion transport	1
action potential	1
cell communication	1
chemical synaptic transmission	1
nervous system process	1
regulation of RNA stability	1
regulation of mRNA catabolic process	1
synaptic transmission, glutamatergic	1
positive regulation of synaptic transmission	1
regulation of synaptic transmission, glutamatergic	1
neurotransmitter receptor diffusion trapping	1
protein-containing complex localization	1
protein localization to postsynaptic specialization membrane	1
positive regulation of cell growth	1
positive regulation of developmental growth	1
dendrite extension	1
regulation of dendrite extension	1
AMPA glutamate receptor activity	1
regulation of transmembrane transporter activity	1
regulation of neurotransmitter receptor activity	1
transport	1
monoatomic ion transport	1
transmembrane transport	1
calcium ion transport	1
monoatomic cation transmembrane transport	1
voltage-gated monoatomic cation channel activity	1
ion channel regulator activity	1
channel activity	1
transporter regulator activity	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
binding	1
endosome	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

2128 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACNG7	CACNG1	Q06432	917
CACNG7	PRKCG	P05129	802
CACNG7	CACNA1D	Q01668	783
CACNG7	CACNB1	Q02641	751
CACNG7	DLG4	P78352	650
CACNG7	CACNA2D2	Q9NY47	645
CACNG7	CACNA2D1	P54289	644
CACNG7	CACNA1E	Q15878	543
CACNG7	CNIH2	Q6PI25	520
CACNG7	CACNA1G	O43497	512
CACNG7	CACNA1B	Q00975	500
CACNG7	CNIH4	Q9P003	477
CACNG7	CACNG4	Q9UBN1	475
CACNG7	AVPI1	Q5T686	464
CACNG7	ELOC	Q15369	461

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CACNG7	SPACA1	psi-mi:“MI:0915”(physical association)	0.560
CACNG7	PLD2	psi-mi:“MI:0914”(association)	0.350
CACNG7	SPACA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): SPACA1 (Two-hybrid), SLC25A4 (Affinity Capture-MS), TSPYL1 (Affinity Capture-MS), RAB29 (Affinity Capture-MS), CYBA (Affinity Capture-MS), HLA-DRB1 (Affinity Capture-MS), FBXL6 (Affinity Capture-MS), ACSL1 (Affinity Capture-MS), SLC25A6 (Affinity Capture-MS), IQSEC1 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), KIRREL (Affinity Capture-MS), FUT8 (Affinity Capture-MS), SAMM50 (Affinity Capture-MS), SLC38A5 (Affinity Capture-MS)

ESM2 similar proteins: A2AIR5, A5PK40, A6NFX1, B9EKX1, D2HKB0, D3ZG27, F1NCD6, O60242, P23979, P46098, P62955, P62956, P62957, Q08DW9, Q0VBU9, Q13635, Q14B62, Q3T9X0, Q4R766, Q504N2, Q5H8A4, Q5RB09, Q5RIV7, Q5T4D3, Q5VTY9, Q5VYX0, Q5VZY2, Q5ZIN0, Q61115, Q66H95, Q6AYT7, Q6ZW05, Q80ZF8, Q8BG19, Q8BWB6, Q8IZD6, Q8N2K0, Q8N6M3, Q8NEB5, Q8NHX9

Diamond homologs: O60359, O88602, P62955, P62956, P62957, Q0VD05, Q4R589, Q5R5X2, Q71RJ2, Q8VHW2, Q8VHW4, Q8VHW5, Q8VHW8, Q8VHW9, Q8VHX0, Q8WXS5, Q9JJV4, Q9JJV5, Q9UBN1, Q9UF02, Q9Y698

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	37
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
996577	NM_031896.5(CACNG7):c.784A>G (p.Ile262Val)	Likely pathogenic

SpliceAI

1123 predictions. Top by Δscore:

Variant	Effect	Δscore
19:53909516:AGGTG:A	donor_loss	1.0000
19:53909518:G:GA	donor_loss	1.0000
19:53913009:C:T	donor_gain	1.0000
19:53913025:CAGGT:C	donor_loss	1.0000
19:53913027:GG:G	donor_loss	1.0000
19:53913028:GTA:G	donor_loss	1.0000
19:53913029:T:A	donor_loss	1.0000
19:53914583:C:G	donor_gain	1.0000
19:53914585:GA:G	donor_gain	1.0000
19:53914587:G:GG	donor_gain	1.0000
19:53915363:A:AG	acceptor_gain	1.0000
19:53915364:G:GG	acceptor_gain	1.0000
19:53915364:GA:G	acceptor_gain	1.0000
19:53915504:GG:G	donor_gain	1.0000
19:53915505:GG:G	donor_gain	1.0000
19:53915506:G:GC	donor_loss	1.0000
19:53915506:G:GG	donor_gain	1.0000
19:53915507:T:G	donor_loss	1.0000
19:53942031:CGCAG:C	acceptor_loss	1.0000
19:53942032:GCAGG:G	acceptor_loss	1.0000
19:53942034:A:AG	acceptor_gain	1.0000
19:53942034:AG:A	acceptor_gain	1.0000
19:53942034:AGG:A	acceptor_gain	1.0000
19:53942035:G:GG	acceptor_gain	1.0000
19:53942035:GG:G	acceptor_gain	1.0000
19:53942035:GGG:G	acceptor_gain	1.0000
19:53909513:GCGAG:G	donor_gain	0.9900
19:53912801:A:AG	acceptor_gain	0.9900
19:53912802:G:GA	acceptor_loss	0.9900
19:53912802:G:GG	acceptor_gain	0.9900

AlphaMissense

1806 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:53914517:T:A	C72S	1.000
19:53914518:G:C	C72S	1.000
19:53915400:A:C	S107R	1.000
19:53915402:C:A	S107R	1.000
19:53915402:C:G	S107R	1.000
19:53915484:G:C	G135R	1.000
19:53915485:G:A	G135D	1.000
19:53915497:T:A	I139K	1.000
19:53915505:G:C	G142R	1.000
19:53941487:G:C	G148R	1.000
19:53942043:G:A	G193D	1.000
19:53912868:A:C	S13R	0.999
19:53912870:C:A	S13R	0.999
19:53912870:C:G	S13R	0.999
19:53912881:G:A	G17D	0.999
19:53912889:G:C	G20R	0.999
19:53912904:G:C	G25R	0.999
19:53912911:C:A	A27E	0.999
19:53912916:A:C	S29R	0.999
19:53912918:C:A	S29R	0.999
19:53912918:C:G	S29R	0.999
19:53912920:C:T	T30I	0.999
19:53912923:A:T	D31V	0.999
19:53912928:T:A	W33R	0.999
19:53912928:T:C	W33R	0.999
19:53912930:G:C	W33C	0.999
19:53912930:G:T	W33C	0.999
19:53912932:T:C	L34P	0.999
19:53913000:G:C	G57R	0.999
19:53913000:G:T	G57C	0.999

dbSNP variants (sampled 300 via entrez): RS1000073509 (19:53928600 T>C), RS1000133518 (19:53913697 T>A,C), RS1000140909 (19:53926092 T>C), RS1000164686 (19:53918849 A>C,G), RS1000195198 (19:53925900 C>T), RS1000209109 (19:53916193 G>A), RS1000247390 (19:53925726 G>A,C,T), RS1000309496 (19:53913129 G>A,C), RS1000398555 (19:53931135 G>A,T), RS1000646668 (19:53911715 G>A,T), RS1000680830 (19:53929934 T>C), RS1000829273 (19:53917313 T>C), RS1000841551 (19:53936938 C>G), RS1000874020 (19:53936758 A>G), RS1000891901 (19:53918684 C>T)

Disease associations

OMIM: gene MIM:606899 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2363032 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 67,947 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1428	NIMODIPINE	4	32,587
CHEMBL95	TACRINE	4	35,360

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

58 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CHEMBL3891844
8.72	IC50	1.9	nM	CHEMBL3890624
8.62	IC50	2.4	nM	CHEMBL3973392
8.57	IC50	2.7	nM	CHEMBL3891844
8.52	IC50	3	nM	CHEMBL3919024
8.51	IC50	3.1	nM	CHEMBL3919898
8.35	IC50	4.5	nM	CHEMBL3965812
8.23	IC50	5.9	nM	CHEMBL3906126
8.22	IC50	6	nM	CHEMBL3890916
8.15	IC50	7	nM	CHEMBL3940577
8.14	IC50	7.2	nM	CHEMBL3969562
8.12	IC50	7.6	nM	CHEMBL3937280
8.12	IC50	7.6	nM	CHEMBL3965812
8.10	IC50	8	nM	CHEMBL3983323
8.05	IC50	9	nM	CHEMBL3942512
8.03	IC50	9.4	nM	CHEMBL3922498
8.01	IC50	9.7	nM	CHEMBL3897303
7.96	IC50	11	nM	CHEMBL3948329
7.92	IC50	12	nM	CHEMBL3898359
7.85	IC50	14	nM	CHEMBL3911369
7.85	IC50	14	nM	CHEMBL3913505
7.85	IC50	14	nM	CHEMBL3936725
7.82	IC50	15	nM	CHEMBL3984596
7.82	IC50	15	nM	CHEMBL3902376
7.67	IC50	21.5	nM	CHEMBL3952905
7.62	IC50	24	nM	CHEMBL3972896
7.58	IC50	26	nM	CHEMBL3889804
7.55	IC50	28	nM	CHEMBL3958844
7.55	IC50	28	nM	CHEMBL3973382
7.52	IC50	30	nM	CHEMBL3978200
7.52	IC50	30	nM	CHEMBL3985660
7.51	IC50	31	nM	CHEMBL3896861
7.51	IC50	31	nM	CHEMBL3951956
7.50	IC50	31.4	nM	CHEMBL3962403
7.44	IC50	36	nM	CHEMBL3953976
7.44	IC50	36	nM	CHEMBL3925140
7.41	IC50	39	nM	CHEMBL3900691
7.39	IC50	41	nM	CHEMBL3930781
7.30	IC50	50	nM	CHEMBL3921840
7.21	IC50	62	nM	CHEMBL3956991
7.17	IC50	67	nM	CHEMBL3965293
7.09	IC50	81	nM	CHEMBL3958264
7.07	IC50	85	nM	CHEMBL3964411
7.01	IC50	98.5	nM	CHEMBL3953031
6.40	IC50	400	nM	CHEMBL3974355
6.10	IC50	800	nM	CHEMBL3734797
5.75	IC50	1800	nM	CHEMBL4228929
5.66	IC50	2200	nM	CHEMBL4226021
5.52	IC50	3000	nM	CHEMBL4228209
5.52	IC50	3000	nM	CHEMBL4224773

PubChem BioAssay actives

13 with measured affinity, of 101 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-tert-butyl-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide	1262825: Inhibition of voltage-gated calcium channel (unknown origin)	ic50	0.8000	uM
5-methyl-1-[(2-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	1.8000	uM
1-[(3-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	2.2000	uM
5-methyl-1-[(3-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-[(4-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-benzyl-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.4000	uM
5-methyl-1-[(4-methylphenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.6000	uM
1-[(4-fluorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	4.8000	uM
N-heptyl-16,18-dioxo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-hexaene-1-carboxamide	1612587: Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	ic50	9.0000	uM
ethyl 5-amino-4-(3-methoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
ethyl 5-amino-4-(3,4-dimethoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
propan-2-yl 5-amino-2-methyl-4-phenyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM
ethyl 5-amino-2-methyl-4-phenyl-6,7,8,9,10,11-hexahydrocycloocta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
propionaldehyde	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arbutin	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Diethylhexyl Phthalate	decreases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Silicon Dioxide	increases expression	1
Dronabinol	increases expression	1
Aflatoxin B1	decreases methylation	1
Acrylamide	decreases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3737861	Binding	Inhibition of voltage-gated calcium channel (unknown origin)	Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors. — J Med Chem

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7LG	Ubigene A-549 CACNG7 KO	Cancer cell line	Male
CVCL_YA31	IDG-HEK293T-CACNG7-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders